Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Rosacea Treatment Market

Rosacea Treatment Market Share

Report ID: GMI10190
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Rosacea Treatment Market Share

The rosacea treatment industry is competitive in nature, with various large multinationals and small and mid-sized companies competing in the industry. The development and launch of novel treatments with improved efficiency and cost-effectiveness are key market strategies for rosacea treatment product manufacturers, driving competition and innovation in the industry. This emphasis on innovation aims to address evolving clinical needs and enhance patient outcomes, positioning companies to gain market share and meet the growing demand for novel rosacea treatments.

Rosacea Treatment Market Companies

Some of the eminent market participants operating in the industry include:

Aclaris Therapeutics
Colorescience, Inc.
Croda International Plc
Dr. Reddy’s Laboratories Ltd
Galderma
Journey Medical Corporation
Leopharma
Lupin
Maruho Co.,Ltd.
Merck & Co., Inc
Mylan N.V.
Perrigo Company plc
PRUGEN
Sol-Gel Technologies Ltd

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Industry size for rosacea treatment was worth USD 2.1 billion in 2023 and is projected to expand at 6.5% CAGR from 2024 to 2032, due to the increasing prevalence of rosacea.

The ETR (erythematotelangiectatic rosacea) segment in the rosacea treatment industry accounted for 35.2% share in 2023 and is estimated to grow at significant CAGR from 2024 to 2032, as the early diagnosis and treatment can help manage symptoms and prevent progressions.

The antibiotics drug class segment in the rosacea treatment market recorded USD 617.5 million in 2023 as they possess significant anti-inflammatory properties, which are essential for managing the chronic inflammation associated with rosacea.

North America market amassed USD 897.7 million in revenue in 2023 and is projected to depict substantial gains from 2024 to 2032, due to the rising R&D efforts undertaken in the region.